SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX ), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that preclinical results will be presented at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place October 26-30 in Philadelphia.
Abstract Information:
| Title: | EGFR-CD3 bispecific Probody therapeutic induces tumor regressions and increases maximum tolerated dose >60 fold in preclinical studies |
| Session Category: | EGFR/Her2 |
| Date: | Saturday, October 28 |
| Time: | Poster Session A: 12:30 p.m. – 4:00 p.m. |
| Location: | Hall E, Pennsylvania Convention Center |
| Abstract: | A164 |
The EGFR-CD3 bispecific Probody therapeutic poster will also be included in the Spotlight on Proffered Papers session starting at 10:50 a.m. on Friday, October 27 in the Terrance Ballroom, 400 level.
| Title: | Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates |
| Session Category: | Therapeutic Agents: Biological |
| Date: | Sunday, October 29 |
| Time: | Poster Session B: 12:30 p.m. – 4:00 p.m. |
| Location: | Hall E, Pennsylvania Convention Center |
| Abstract: | B116 |
| Title: | A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate (PDC) in preclinical studies |
| Session Category: | Therapeutic Agents: Biological |
| Date: | Sunday, October 29 |
| Time: | Poster Session B: 12:30 p.m. – 4:00 p.m. |
| Location: | Hall E, Pennsylvania Convention Center |
| Abstract: | B103 |
| Title: | Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys |
| Session Category: | Therapeutic Agents: Biological |
| Date: | Sunday, October 29 |
| Time: | Poster Session B: 12:30 p.m. – 4:00 p.m. |
| Location: | Hall E, Pennsylvania Convention Center |
| Abstract: | LB-B33 |
About CytomX Therapeutics CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1 and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter .
Media Contact: Spectrum Amir Khan akhan@spectrumscience.com 212-899-9730
Investor Contact: Trout Group Pete Rahmer prahmer@troutgroup.com 646-378-2973
